Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: Comparison with liquid chromatography/mass spectrometry

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 149-154

  Dasgupta, Amitava ^a   Davis, Bonnet ^b   Chow, Loretta ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

everolimus; immunoassay; liquid chromatography mass spectrometry

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMPHOTERICIN B; ATENOLOL; CAPTOPRIL; CEFACLOR; CIMETIDINE; CYCLOSPORIN A; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; FUROSEMIDE; GENTAMICIN; HEPARIN; IBUPROFEN; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MEVINOLIN; MISOPROSTOL; NAPROXEN; NIFEDIPINE; PARACETAMOL; PHENYTOIN; PREDNISONE; RANITIDINE; RAPAMYCIN; TACROLIMUS; UNINDEXED DRUG;

ANALYZER; ARTICLE; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG MONITORING; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY; SIROLIMUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79953194044     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820afc97     Document Type: Article

References (16)

1. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc. 2004;36(Suppl 2S):S500-S503.
2. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95. (Pubitemid 38283132)
3. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42. (Pubitemid 27327197)
4. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three dosages on the incidence and severity of acute rejection. Transplantation. 2001;71:1400-1406. (Pubitemid 32507112)
5. Neumayer HH, Paradis K, Korn A, et al. Entry into human study with the novel immunosuppressant SDA RAD in stable renal transplant recipients. Br J Clin Pharmacol. 1999;48:694-703. (Pubitemid 29520593)
6. Deters M, Kirchner G, Resch K, et al. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography- mass spectrometry. Clin Chem Lab Med. 2002;40:285-292. (Pubitemid 34428858)
7. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: pharmacokinetics, exposure response relationships and influence on cyclosporine. Clin Pharmacol Ther. 2001;69:48-56. (Pubitemid 32108671)
8. Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of everolimus in solid organ transplantation. Ther Drug Monit. 2005;27: 666-676. (Pubitemid 41437646)
9. Christians U, Jacobsen W, Serkova N, et al. Automated fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B. 2000;748:41-53.
10. Korecha M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant. 2009;14:61-72.
11. Moes DJ, Press RR, de Fijter JW, et al. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther Drug Monit. 2010;32:413-419.
12. Holt DW, McKeown DA, Lee TD, et al. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant Proc. 2004;36:3223-3225. (Pubitemid 41126778)
13. Romagnoli J, Citterio F, Favi E, et al. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure. Transplant Proc. 2007;39:1823-1826. (Pubitemid 47198829)
14. Schmid RW, Lotz J, Schweigert R, et al. Multi-site analytical evaluation of a chemiluminescent microparticle immunoassay (CMIA) for sirolimus on the Abbott Architect analyzer. Clin Biochem. 2009;42:1543-1548.
15. Salm P,Warnholtz C, Boyd J, et al. Evaluation of a fluorescence polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39:732-738. (Pubitemid 44036785)
16. Koster RA, Dijkers EC, Uges DR. Robust high throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus and sirolimus in whole blood. Ther Drug Monit. 2009;31:116-125.